

Remarks

After entry of the above amendment, claims 1 to 35 and 48 will be pending in this application.

Claims 1 to 4, 17 to 22, 26, 28 to 30, and 34 are original claims.

Claims 5 to 16, 23 to 25, 27, 31 to 33, 35, and 48 have been amended.

Claims 36 to 47 have been cancelled without prejudice.


The amended claims have been amended merely to remove or reduce multiple dependencies.

The specification has been amended to add the "Cross Reference to Related Application" section showing that this application is claiming priority to an earlier U.S. provisional application.

It is respectfully submitted that no new matter has been added by way of this amendment. The Commissioner is hereby authorized to charge any fees under 37 CFR §§1.16, 1.17, and 1.492 as required by this paper to Deposit Account No. 50-1441.

Respectfully submitted,

Date: May 10, 2006



Melody E. Clark, Ph.D.
Registration No. 51,566

Arena Pharmaceuticals, Inc.
6166 Nancy Ridge Drive
San Diego, CA 92121
Telephone: (858) 453-7200 x1597
Facsimile: (858) 677-0065